<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35062706</PMID><DateRevised><Year>2022</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">46</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines10010046</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Few data are available concerning the effect of SARS-CoV-2 vaccination on the persistent symptoms associated with COVID-19, also called long-COVID or post-acute sequelae of COVID-19 (PASC).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We conducted a nationwide online study among adult patients with PASC as defined by symptoms persisting over 4 weeks following a confirmed or probable COVID-19, without any identified alternative diagnosis. Information concerning PASC symptoms, vaccine type and scheme and its effect on PASC symptoms were studied.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">620 questionnaires were completed and 567 satisfied the inclusion criteria and were analyzed. The respondents' median age was 44 (IQR 25-75: 37-50) and 83.4% were women. The initial infection was proven in 365 patients (64%) and 5.1% had been hospitalized to receive oxygen. A total of 396 patients had received at least one injection of SARS-CoV-2 vaccine at the time of the survey, after a median of 357 (198-431) days following the initially-reported SARS-CoV-2 infection. Among the 380 patients who reported persistent symptoms at the time of SARS-CoV-2 vaccination, 201 (52.8%) reported a global effect on symptoms following the injection, corresponding to an improvement in 21.8% and a worsening in 31%. There were no differences based on the type of vaccine used. After a complete vaccination scheme, 93.3% (28/30) of initially seronegative patients reported a positive anti-SARS-CoV-2 IgG. A total of 170 PASC patients had not been vaccinated. The most common reasons for postponing the SARS-CoV-2 vaccine were fear of worsening PASC symptoms (55.9%) and the belief that vaccination was contraindicated because of PASC (15.6%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study suggests that SARS-CoV-2 vaccination is well tolerated in the majority of PASC patients and has good immunogenicity. Disseminating these reassuring data might prove crucial to increasing vaccine coverage in patients with PASC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scherlinger</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9453-5895</Identifier><AffiliationInfo><Affiliation>Rheumatology Department, Centre Hospitalier Universitaire de Strasbourg, 1 Avenue Moli&#xe8;re, 67098 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de R&#xe9;f&#xe9;rence des Maladies Auto-Immunes et Syst&#xe9;miques Rares, Est/Sud-Ouest (RESO), 67000 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centre Hospitalier Universitaire de Strasbourg, 1 Avenue Moli&#xe8;re, 67098 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de R&#xe9;f&#xe9;rence des Maladies Auto-Immunes et Syst&#xe9;miques Rares, Est/Sud-Ouest (RESO), 67000 Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatelus</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centre Hospitalier Universitaire de Strasbourg, 1 Avenue Moli&#xe8;re, 67098 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de R&#xe9;f&#xe9;rence des Maladies Auto-Immunes et Syst&#xe9;miques Rares, Est/Sud-Ouest (RESO), 67000 Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnaud</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centre Hospitalier Universitaire de Strasbourg, 1 Avenue Moli&#xe8;re, 67098 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de R&#xe9;f&#xe9;rence des Maladies Auto-Immunes et Syst&#xe9;miques Rares, Est/Sud-Ouest (RESO), 67000 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire d'ImmunoRhumatologie Mol&#xe9;culaire, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM) UMR_S 1109, Institut Th&#xe9;matique Interdisciplinaire (ITI) de M&#xe9;decine de Pr&#xe9;cision de Strasbourg, Transplantex NG, Facult&#xe9; de M&#xe9;decine, F&#xe9;d&#xe9;ration Hospitalo-Universitaire OMICARE, F&#xe9;d&#xe9;ration de M&#xe9;decine Translationnelle de Strasbourg (FMTS), Universit&#xe9; de Strasbourg, 1 rue Eug&#xe8;ne Boeckel, 67084 Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottenberg</LastName><ForeName>Jacques-Eric</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centre Hospitalier Universitaire de Strasbourg, 1 Avenue Moli&#xe8;re, 67098 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de R&#xe9;f&#xe9;rence des Maladies Auto-Immunes et Syst&#xe9;miques Rares, Est/Sud-Ouest (RESO), 67000 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IBMC, UPR3572, CNRS, 2 all&#xe9;e Konrad Roentgen, 67084 Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sibilia</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centre Hospitalier Universitaire de Strasbourg, 1 Avenue Moli&#xe8;re, 67098 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de R&#xe9;f&#xe9;rence des Maladies Auto-Immunes et Syst&#xe9;miques Rares, Est/Sud-Ouest (RESO), 67000 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire d'ImmunoRhumatologie Mol&#xe9;culaire, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM) UMR_S 1109, Institut Th&#xe9;matique Interdisciplinaire (ITI) de M&#xe9;decine de Pr&#xe9;cision de Strasbourg, Transplantex NG, Facult&#xe9; de M&#xe9;decine, F&#xe9;d&#xe9;ration Hospitalo-Universitaire OMICARE, F&#xe9;d&#xe9;ration de M&#xe9;decine Translationnelle de Strasbourg (FMTS), Universit&#xe9; de Strasbourg, 1 rue Eug&#xe8;ne Boeckel, 67084 Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felten</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4951-4032</Identifier><AffiliationInfo><Affiliation>Rheumatology Department, Centre Hospitalier Universitaire de Strasbourg, 1 Avenue Moli&#xe8;re, 67098 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre National de R&#xe9;f&#xe9;rence des Maladies Auto-Immunes et Syst&#xe9;miques Rares, Est/Sud-Ouest (RESO), 67000 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IBMC, UPR3572, CNRS, 2 all&#xe9;e Konrad Roentgen, 67084 Strasbourg, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID-19</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35062706</ArticleId><ArticleId IdType="pmc">PMC8781023</ArticleId><ArticleId IdType="doi">10.3390/vaccines10010046</ArticleId><ArticleId IdType="pii">vaccines10010046</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prevalence of Long COVID Symptoms and COVID-19 Complications&#x2014;Office for National Statistics.  [(accessed on 16 December 2020)]; Available online:  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications.</Citation></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., Lekoubou A., Oh J.S., Ericson J.E., Ssentongo P., et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw. Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M., Felten R., Gallais F., Nazon C., Chatelus E., Pijnenburg L., Mengin A., Gras A., Vidailhet P., Arnould-Michel R., et al. Refining &#x201c;Long-COVID&#x201d; by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. Infect. Dis. Ther. 2021;10:1747&#x2013;1763. doi: 10.1007/s40121-021-00484-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00484-w</ArticleId><ArticleId IdType="pmc">PMC8270770</ArticleId><ArticleId IdType="pubmed">34245450</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold C.G., Monte A.A., Littlefield K., Vest A., Palmer B.E. Vaccination Hesitancy and Postacute Sequelae of SARS-CoV-2: Is It Time to Reconsider? Viral Immunol. 2021;34:666&#x2013;668. doi: 10.1089/vim.2021.0126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2021.0126</ArticleId><ArticleId IdType="pmc">PMC8851407</ArticleId><ArticleId IdType="pubmed">34491119</ArticleId></ArticleIdList></Reference><Reference><Citation>Desimmie B.A., Raru Y.Y., Awadh H.M., He P., Teka S., Willenburg K.S. Insights into SARS-CoV-2 Persistence and Its Relevance. Viruses. 2021;13:1025. doi: 10.3390/v13061025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061025</ArticleId><ArticleId IdType="pmc">PMC8228265</ArticleId><ArticleId IdType="pubmed">34072390</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Milne A., Stadon L., Maskell N.A., Hamilton F.W. Are vaccines safe in patients with Long COVID? A prospective observational study. medRxiv. 2021 doi: 10.1101/2021.03.11.21253225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21253225</ArticleId></ArticleIdList></Reference><Reference><Citation>HAS  Sympt&#xf4;mes Prolong&#xe9;s Suite &#xe0; une COVID-19 de L&#x2019;adulte&#x2014;Diagnostic et Prise en Charge. Haute Autorit&#xe9; de Sant&#xe9;. 2021.  [(accessed on 24 June 2021)].  Available online:  https://www.has-sante.fr/jcms/p_3237041/fr/symptomes-prolonges-suite-a-une-covid-19-de-l-adulte-diagnostic-et-prise-en-charge.</Citation></Reference><Reference><Citation>Tran V.T., Riveros C., Clepier B., Desvarieux M., Collet C., Yordanov Y., Ravaud P. Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients&#x2019; lived experience. Clin. Infect. Dis. 2021 doi: 10.1093/cid/ciab352. epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta J., Wiernik E., Robineau O., Carrat F., Touvier M., Severi G., de Lamballerie X., Blanch&#xe9; H., Deleuze J.F., Gouraud C., et al. Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. JAMA Intern. Med. 2021:e216454. doi: 10.1001/jamainternmed.2021.6454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6454</ArticleId><ArticleId IdType="pmc">PMC8576624</ArticleId><ArticleId IdType="pubmed">34747982</ArticleId></ArticleIdList></Reference><Reference><Citation>Machingaidze S., Wiysonge C.S. Understanding COVID-19 vaccine hesitancy. Nat. Med. 2021;27:1338&#x2013;1339. doi: 10.1038/s41591-021-01459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01459-7</ArticleId><ArticleId IdType="pubmed">34272500</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., Palese A., Venturini M., De Martino M., Gerussi V., Graziano E., Bontempo G., Marrella F., Tommasini A., Fabris M., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin. Microbiol. Infect. 2021;27:1507&#x2013;1513. doi: 10.1016/j.cmi.2021.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray-Burrows K.A., Willis T.A., Foy R., Rathfelder M., Bland P., Chin A., Hodgson S., Ibegbuna G., Prestwich G., Samuel K., et al. Role of patient and public involvement in implementation research: A consensus study. BMJ Qual. Saf. 2018;27:858&#x2013;864. doi: 10.1136/bmjqs-2017-006954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjqs-2017-006954</ArticleId><ArticleId IdType="pmc">PMC6166593</ArticleId><ArticleId IdType="pubmed">29666310</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>